

Manuel Barreiro-de Acosta

List of Publications by Citations

Source: <https://exaly.com/author-pdf/437983/manuel-barreiro-de-acosta-publications-by-citations.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

47 papers	1,039 citations	13 h-index	32 g-index
64 ext. papers	1,400 ext. citations	2.4 avg, IF	3.56 L-index

#	Paper	IF	Citations
47	The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. <i>Journal of Crohns and Colitis</i> , 2016 , 10, 239-54	1.5	354
46	Evaluation of the Risk of Relapse in Ulcerative Colitis According to the Degree of Mucosal Healing (Mayo 0 vs 1): A Longitudinal Cohort Study. <i>Journal of Crohns and Colitis</i> , 2016 , 10, 13-9	1.5	107
45	Mucosal healing restores normal health and quality of life in patients with inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2012 , 24, 762-9	2.2	77
44	Delphi consensus statement: Quality Indicators for Inflammatory Bowel Disease Comprehensive Care Units. <i>Journal of Crohns and Colitis</i> , 2014 , 8, 240-51	1.5	65
43	Psychological factors are associated with changes in the health-related quality of life in inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2014 , 20, 92-102	4.5	63
42	Efficacy of adalimumab rescue therapy in patients with chronic refractory pouchitis previously treated with infliximab: a case series. <i>European Journal of Gastroenterology and Hepatology</i> , 2012 , 24, 756-8	2.2	51
41	Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2017 , 23, 1394-1402	4.5	47
40	Does smoking influence Crohn's disease in the biologic era? The TABACROHN study. <i>Inflammatory Bowel Diseases</i> , 2013 , 19, 23-9	4.5	34
39	Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose Escalation. <i>Digestive Diseases and Sciences</i> , 2017 , 62, 481-490	4	31
38	Ulcerative colitis in northern Portugal and Galicia in Spain. <i>Inflammatory Bowel Diseases</i> , 2010 , 16, 1227-35	4.5	22
37	Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2015 , 60, 3075-84	4	21
36	Characteristics and Progression of Preclinical Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 1459-1466	6.9	19
35	Effectiveness of ustekinumab dose escalation in Crohn's disease patients with insufficient response to standard-dose subcutaneous maintenance therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 135-142	6.1	17
34	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) and the Association of Crohn's Disease and Ulcerative Colitis Patients (ACCU) in the management of psychological problems in Inflammatory Bowel Disease patients. <i>Gastroenterology and Hepatology</i> , 2018 , 41, 1118-127	0.9	13
33	A pharmacogenetics study of TPMT and ITPA genes detects a relationship with side effects and clinical response in patients with inflammatory bowel disease receiving Azathioprine. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2011 , 20, 247-53	1.4	12
32	Influence of alexithymia on health-related quality of life in inflammatory bowel disease: are there any related factors?. <i>Scandinavian Journal of Gastroenterology</i> , 2012 , 47, 445-53	2.4	11
31	Perioperative management and early complications after intestinal resection with ileocolonic anastomosis in Crohn's disease: analysis from the PRACTICROHN study. <i>Gastroenterology Report</i> , 2019 , 7, 168-175	3.3	10

30	How do psychological variables influence coping strategies in inflammatory bowel disease?. <i>Journal of Crohns and Colitis</i> , 2013 , 7, e219-26	1.5	10
29	EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain. <i>Therapeutic Advances in Gastroenterology</i> , 2019 , 12, 1756284819847034	4.7	9
28	Clinical applications of NOD2/CARD15 mutations in Crohn's disease. <i>Acta Gastroenterologica Latinoamericana</i> , 2007 , 37, 49-54	1	7
27	NOD2/CARD15: geographic differences in the Spanish population and clinical applications in Crohn's disease. <i>Revista Espanola De Enfermedades Digestivas</i> , 2010 , 102, 321-6	0.9	6
26	Inflammatory bowel disease integral care units: Evaluation of a nationwide quality certification programme. The GETECCU experience. <i>United European Gastroenterology Journal</i> , 2021 , 9, 766	5.3	6
25	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on pouchitis in ulcerative colitis. Part 1: Epidemiology, diagnosis and prognosis. <i>Gastroenterología Y Hepatología</i> , 2019 , 42, 568-578	0.9	5
24	Clinical status, quality of life, and work productivity in Crohn's disease patients after one year of treatment with adalimumab. <i>Revista Espanola De Enfermedades Digestivas</i> , 2017 , 109, 122-129	0.9	5
23	Resumption of activity in gastroenterology departments. Recommendations by SEPD, AEEH, GETECCU and AEG. <i>Revista Espanola De Enfermedades Digestivas</i> , 2020 , 112, 397-411	0.9	5
22	COVID-19 and inflammatory bowel disease: questions arising from patient care and follow-up during the initial phase of the pandemic (February-April 2020). <i>Gastroenterología Y Hepatología</i> , 2020 , 43, 408-413	0.9	4
21	COVID-19-related personal product shortages are associated with psychological distress in people living with gastrointestinal disorders: A cross-sectional survey. <i>Neurogastroenterology and Motility</i> , 2021 , e14198	4	3
20	SARS-CoV-2 vaccine acceptance among gastroenterologists and inflammatory bowel disease patients: VACUNEII project. <i>Gastroenterología Y Hepatología</i> , 2021 ,	0.9	3
19	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) and the Association of Crohn's Disease and Ulcerative Colitis Patients (ACCU) in the management of psychological problems in Inflammatory Bowel Disease patients. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2020 , 43, 408-413	0.1	2
18	COVID-19 and inflammatory bowel disease: Questions arising from patient care and follow-up during the initial phase of the pandemic (February-April 2020). <i>Gastroenterología Y Hepatología (English Edition)</i> , 2020 , 43, 408-413	0.1	2
17	Targeted H NMR metabolomics and immunological phenotyping of human fresh blood and serum samples discriminate between healthy individuals and inflammatory bowel disease patients treated with anti-TNF. <i>Journal of Molecular Medicine</i> , 2021 , 99, 1251-1264	5.5	2
16	Effectiveness of Third-Class Biologic Treatment in Crohn's Disease: A Multi-Center Retrospective Cohort Study. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	2
15	Role of Quality of Life as Endpoint for Inflammatory Bowel Disease Treatment. <i>International Journal of Environmental Research and Public Health</i> , 2021 , 18,	4.6	2
14	The impact of the coronavirus (COVID-19) pandemic on individuals with gastrointestinal disorders: A protocol of an international collaborative study. <i>Journal of Psychosomatic Research</i> , 2021 , 148, 110561	4.1	2
13	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on pouchitis in ulcerative colitis. Part 2: Treatment. <i>Gastroenterología Y Hepatología</i> , 2020 , 43, 649-658	0.9	1

12	Letter: predictors of severe disease in ulcerative colitis - the same or different in Crohn's disease?. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 40, 1120-1	6.1	1
11	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on pouchitis in ulcerative colitis. Part 1: Epidemiology, diagnosis and prognosis. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2019 , 42, 568-578	0.1	1
10	Extending the Common Sense Model to Explore the Impact of the Fear of COVID-19 on Quality of Life in an International Inflammatory Bowel Disease Cohort. <i>Journal of Clinical Psychology in Medical Settings</i> , 2021 , 1	2	1
9	Impact of Biological Agents on Postsurgical Complications in Inflammatory Bowel Disease: A Multicentre Study of Geteccu. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	1
8	Risk of immunomediated adverse events and loss of response to infliximab in elderly patients with inflammatory bowel disease. A cohort study of the ENEIDA registry. <i>Journal of Crohns and Colitis</i> , 2021 ,	1.5	1
7	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on pouchitis in ulcerative colitis. Part 2: Treatment. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2020 , 43, 649-658	0.1	0
6	Pouchitis: Treatment dilemmas at different stages of the disease. <i>United European Gastroenterology Journal</i> , 2020 , 8, 256-262	5.3	0
5	Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients.. <i>Frontiers in Medicine</i> , 2022 , 9, 823900	4.9	0
4	Thiopurines: Use them or lose them? International survey on current and future use of thiopurines in inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2021 , 53, 1571-1579	3.3	0
3	Increased use of healthcare resources during the preclinical period of inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2021 , 53, 927-930	3.3	0
2	Comment to "Biosimilars: The viewpoint of Italian patients with inflammatory bowel disease". <i>Digestive and Liver Disease</i> , 2020 , 52, 1302-1303	3.3	
1	Risk of Depression During the Natural History of Inflammatory Bowel Disease: The Phantom Menace. <i>Inflammatory Bowel Diseases</i> , 2021 , 27, e99-e100	4.5	